Overview
Bausch Health Companies Inc., headquartered in Canada, operates as a diverse multinational company primarily in the pharmaceutical sector with additional key interests in medical devices and over-the-counter products. The company actively develops, manufactures, and markets a range of products that aim to improve patients' health. Key projects and initiatives include significant investment in R&D for dermatology and eye health products, reflecting the company’s commitment to innovation in specialized areas of healthcare. Baus separated its eye health business into an independent entity, Bausch + Lomb, enhancing its strategic focus and operational flexibility. Bausch Health's strategic endeavors entail pursuing growth through a mixed approach of organic development and acquisitions, which ensures its sustainment and expansion in various global healthcare markets.
Basic Stats
The share price of Bausch Health Companies Inc. as of September 4, 2025 is $9.98 / share. This is a decrease of -1.77% from the prior week. The market cap (or net worth) of Bausch Health Companies Inc. as of September 5, 2025 is $3,690.10 MM.
The Factor Analysis chart (below right) shows a view of Bausch Health Companies Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 3,690.10 MM |
| EV | |
| Shares Out. | 369.75 MM |
| Earnings Date | |
| EPS (TTM) | 0.27 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.83 |
| Short Shares Avail. | 0.01 MM |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 19.38 % |
| Volatility (1 yr) | 0.58 |
| Beta | 0.63 |
| Sharpe Ratio (1 yr) | 0.26 |
| Sortino Ratio (1 yr) | 0.47 |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.00 |
| ROE | |
| ROIC | 0.00 |
| CROIC | 0.05 |
| OCROIC | 0.07 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 81.64 /100 |
| Profitability | 54.70 /100 |
| Quality Score | 48.10 /100 |
| Value Score | |
| Momentum Score | 76.22 /100 |
| Stability (Low Vol) Score | 30.70 /100 |
| Analyst Sentiment | 16.34 /100 |
| Fund Sentiment | 66.44 /100 |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Bausch Health Companies Inc. is $7.35. The forecasts range from a low of $7.28 to a high of $7.57. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Bausch Health Companies Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-12-21 | TRUIST SECURITIES | Hold | Hold | Maintains |
| 2023-09-29 | CRISPIDEA PRIVATE LIMITED | Buy | Buy | Maintains |
| 2023-08-03 | TRUIST SECURITIES | Hold | Hold | Maintains |
| 2023-08-02 | TRUIST SECURITIES | Hold | Hold | Maintains |
| 2023-06-19 | CRISPIDEA PRIVATE LIMITED | Buy | Buy | Maintains |
| 2023-06-18 | CRISPIDEA PRIVATE LIMITED | Buy | Buy | Maintains |
| 2023-05-30 | TRUIST SECURITIES | Buy | Hold | Downgrade |
| 2023-05-29 | TRUIST SECURITIES | Buy | Hold | Downgrade |
| 2023-04-21 | TD COWEN | Outperform | Outperform | Maintains |
| 2023-04-21 | COWEN AND COMPANY | Outperform | Outperform | Maintains |
| 2023-04-20 | TD COWEN | Outperform | Outperform | Maintains |
| 2023-04-20 | COWEN AND COMPANY | Outperform | Outperform | Maintains |
| 2023-04-16 | CRISPIDEA PRIVATE LIMITED | Buy | Buy | Maintains |
| 2023-04-15 | CRISPIDEA PRIVATE LIMITED | Buy | Buy | Maintains |
| 2023-04-06 | TRUIST SECURITIES | Buy | Hold | Downgrade |
| 2023-02-27 | COWEN AND COMPANY | Outperform | Outperform | Maintains |
| 2023-02-24 | STIFEL NICOLAUS AND COMPANY, INCORPORATED | Buy | Buy | Maintains |
| 2023-02-23 | STIFEL NICOLAUS AND COMPANY, INCORPORATED | Buy | Buy | Maintains |
| 2022-05-05 | Morningstar | Buy | Initiate | |
| 2022-02-23 | TRUIST SECURITIES | Buy | Buy | Maintains |
| 2022-02-22 | TRUIST SECURITIES | Buy | Buy | Maintains |
| 2021-04-30 | RBC Capital | Outperform | Maintains | |
| 2020-11-05 | Piper Sandler | Overweight | Maintains | |
| 2020-10-28 | Wells Fargo | Equal-Weight | Maintains | |
| 2020-09-17 | B of A Securities | Underperform | Neutral | Upgrade |
| 2020-08-24 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-08-19 | Piper Sandler | Overweight | Maintains | |
| 2020-08-10 | Citigroup | Buy | Maintains | |
| 2020-07-07 | B of A Securities | Underperform | Maintains | |
| 2020-06-17 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-05-08 | RBC Capital | Sector Perform | Maintains | |
| 2020-04-30 | Wells Fargo | Equal-Weight | Maintains | |
| 2020-04-28 | RBC Capital | Sector Perform | Maintains | |
| 2020-04-23 | Jefferies | Buy | Maintains | |
| 2020-03-23 | Wells Fargo | Equal-Weight | Maintains | |
| 2020-03-23 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-02-20 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2020-02-12 | Morgan Stanley | Overweight | Maintains | |
| 2020-02-11 | Morgan Stanley | Overweight | Maintains | |
| 2020-01-29 | Wolfe Research | Outperform | Peer Perform | Downgrade |
| 2019-12-30 | PiperJaffray | Overweight | Maintains | |
| 2019-12-12 | JP Morgan | Neutral | Overweight | Upgrade |
| 2019-12-02 | Goldman Sachs | Neutral | Initiate | |
| 2019-12-02 | H.C. Wainwright | Buy | Reiterate | |
| 2019-10-25 | Cowen & Co. | Outperform | Initiate | |
| 2019-09-12 | Guggenheim Securities | Buy | Initiate | |
| 2019-08-15 | TD Securities | Hold | Buy | Upgrade |
| 2019-08-07 | H.C. Wainwright | Buy | Maintains | |
| 2019-06-11 | Barclays | 31 | 28 | Downgrade |
| 2019-05-13 | JP Morgan | Underweight | Neutral | Upgrade |
| 2019-03-20 | SunTrust Robinson Humphrey | Buy | Initiate | |
| 2019-02-21 | BMO Capital Markets | 26 | 25 | Downgrade |
| 2019-01-02 | PiperJaffray | Neutral | Overweight | Upgrade |
| 2018-12-14 | H.C. Wainwright | Neutral | Buy | Upgrade |
| 2018-11-30 | Mizuho | Buy | Buy | Maintains |
| 2018-11-05 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2018-10-08 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2018-09-13 | PiperJaffray | Underweight | Neutral | Upgrade |
| 2018-08-13 | BMO Capital | Market Perform | Market Perform | Maintains |
| 2018-06-22 | TD Securities | Buy | Hold | Downgrade |
| 2018-06-06 | Barclays | Equal-Weight | Overweight | Upgrade |
| 2018-05-15 | Mizuho | Neutral | Buy | Upgrade |
| 2018-04-06 | Mizuho | Underperform | Neutral | Upgrade |
| 2018-03-05 | Deutsche Bank | Hold | Buy | Upgrade |
| 2018-01-24 | Goldman Sachs | Sell | Initiate | |
| 2017-12-14 | JP Morgan | Neutral | Underweight | Downgrade |
| 2017-11-16 | Deutsche Bank | Hold | Maintains | |
| 2017-11-13 | BMO Capital | Market Perform | Maintains | |
| 2017-07-17 | Deutsche Bank | Hold | Maintains | |
| 2017-06-16 | Cantor Fitzgerald | Overweight | Initiate | |
| 2016-12-15 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2016-11-23 | Mizuho | Neutral | Underperform | Downgrade |
| 2016-11-10 | Rodman & Renshaw | Buy | Neutral | Downgrade |
| 2016-11-10 | Morgan Stanley | Overweight | Maintains | |
| 2016-09-20 | Deutsche Bank | Hold | Initiate | |
| 2016-08-17 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2016-08-15 | Mizuho | Underperform | Neutral | Upgrade |
| 2016-08-09 | Rodman & Renshaw | Buy | Maintains | |
| 2016-06-29 | BMO Capital | Market Perform | Initiate | |
| 2016-06-23 | JP Morgan | Overweight | Neutral | Downgrade |
| 2016-06-08 | Jefferies | Buy | Maintains | |
| 2016-06-08 | Stifel Nicolaus | Buy | Maintains | |
| 2016-04-11 | Rodman & Renshaw | Buy | Maintains | |
| 2016-03-21 | Barclays | Overweight | Equal-Weight | Downgrade |
| 2016-03-21 | Mizuho | Neutral | Underperform | Downgrade |
| 2016-03-16 | Stifel Nicolaus | Buy | Maintains | |
| 2016-03-16 | RBC Capital | Sector Perform | Maintains | |
| 2016-03-16 | Canaccord Genuity | Hold | Maintains | |
| 2016-03-16 | Nomura | Buy | Neutral | Downgrade |
| 2016-03-16 | JP Morgan | Overweight | Maintains | |
| 2016-03-16 | Rodman & Renshaw | Buy | Maintains | |
| 2016-03-16 | Jefferies | Buy | Maintains | |
| 2016-03-16 | Morgan Stanley | Equal-Weight | Maintains | |
| 2016-03-15 | PiperJaffray | Neutral | Underweight | Downgrade |
| 2016-03-15 | CIBC | Sector Performer | Underperformer | Downgrade |
| 2016-03-08 | Mizuho | Neutral | Maintains | |
| 2016-03-02 | Canaccord Genuity | Buy | Hold | Downgrade |
| 2016-03-01 | Jefferies | Buy | Maintains | |
| 2016-03-01 | RBC Capital | Outperform | Sector Perform | Downgrade |
| 2016-02-29 | TD Securities | Buy | Hold | Downgrade |
| 2016-02-19 | Wells Fargo | Underperform | Initiate | |
| 2016-02-16 | Rodman & Renshaw | Buy | Initiate | |
| 2015-12-17 | Mizuho | Buy | Neutral | Downgrade |
| 2015-12-14 | RBC Capital | Outperform | Maintains | |
| 2015-11-17 | Morgan Stanley | Equal-Weight | Maintains | |
| 2015-11-03 | Deutsche Bank | Hold | Maintains | |
| 2015-11-02 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2015-11-02 | Jefferies | Buy | Maintains | |
| 2015-10-27 | Mizuho | Neutral | Buy | Upgrade |
| 2015-10-20 | Deutsche Bank | Hold | Maintains | |
| 2015-10-20 | JP Morgan | Overweight | Maintains | |
| 2015-10-08 | Mizuho | Neutral | Initiate | |
| 2015-10-02 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2015-09-29 | Nomura | Buy | Initiate | |
| 2015-07-27 | Morgan Stanley | Overweight | Maintains | |
| 2015-07-20 | BTIG Research | Buy | Initiate | |
| 2015-07-20 | RBC Capital | Outperform | Maintains | |
| 2015-05-01 | Stifel Nicolaus | Buy | Maintains | |
| 2015-04-30 | Cantor Fitzgerald | Buy | Maintains | |
| 2015-04-30 | Deutsche Bank | Hold | Maintains | |
| 2015-04-30 | Barclays | Overweight | Maintains | |
| 2015-04-29 | Jefferies | Buy | Maintains | |
| 2015-04-27 | Barclays | Overweight | Maintains | |
| 2015-04-08 | Deutsche Bank | Hold | Maintains | |
| 2015-03-23 | Susquehanna | Positive | Maintains | |
| 2015-02-26 | Morgan Stanley | Overweight | Maintains | |
| 2015-02-24 | Stifel Nicolaus | Buy | Maintains | |
| 2015-02-24 | Barclays | Overweight | Maintains | |
| 2015-02-23 | Cantor Fitzgerald | Buy | Maintains | |
| 2015-02-09 | Barclays | Overweight | Initiate | |
| 2015-01-09 | Jefferies | Buy | Maintains | |
| 2015-01-09 | CRT Capital | Buy | Maintains | |
| 2014-10-21 | Cantor Fitzgerald | Buy | Maintains | |
| 2014-10-21 | Jefferies | Buy | Maintains | |
| 2014-08-01 | UBS | Buy | Maintains | |
| 2014-08-01 | Cantor Fitzgerald | Buy | Maintains | |
| 2014-08-01 | Jefferies | Buy | Maintains | |
| 2014-05-21 | CIBC | Sector Outperform | Initiate | |
| 2014-05-09 | Jefferies | Buy | Maintains | |
| 2014-04-23 | TD Securities | Hold | Buy | Upgrade |
| 2014-04-23 | JP Morgan | Overweight | Maintains | |
| 2014-02-27 | Aegis Capital | Buy | Maintains | |
| 2014-01-08 | TD Securities | Buy | Hold | Downgrade |
| 2014-01-08 | Morgan Stanley | Equal-weight | Overweight | Upgrade |
| 2014-01-08 | BMO Capital | Outperform | Maintains | |
| 2013-10-30 | FBR Capital | Outperform | Initiate | |
| 2013-08-08 | Deutsche Bank | Buy | Maintains | |
| 2013-07-08 | Deutsche Bank | Buy | Maintains | |
| 2013-06-10 | CRT Capital | Fair Value | Buy | Upgrade |
| 2013-05-31 | BMO Capital | Outperform | Initiate | |
| 2013-05-29 | Jefferies | Buy | Maintains | |
| 2013-05-29 | Deutsche Bank | Buy | Maintains | |
| 2013-05-03 | Deutsche Bank | Buy | Maintains | |
| 2013-04-04 | UBS | Buy | Maintains | |
| 2013-04-04 | Deutsche Bank | Buy | Maintains | |
| 2013-03-21 | Deutsche Bank | Buy | Maintains | |
| 2013-03-21 | Paradigm Capital | Buy | Maintains | |
| 2013-02-22 | Aegis Capital | Buy | Initiate | |
| 2013-01-07 | Deutsche Bank | Buy | Maintains | |
| 2012-10-24 | Paradigm Capital | Buy | Maintains | |
| 2012-10-11 | Stifel Nicolaus | Buy | Maintains | |
| 2012-09-17 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2012-09-14 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2012-09-10 | UBS | Buy | Maintains | |
| 2012-09-07 | Jefferies | Buy | Maintains | |
| 2012-09-06 | Jefferies | Buy | Maintains | |
| 2012-09-05 | Paradigm Capital | Buy | Maintains | |
| 2012-09-05 | Bank of America | Underperform | Maintains | |
| 2012-09-05 | UBS | Buy | Maintains | |
| 2012-09-04 | Canaccord Genuity | Buy | Maintains | |
| 2012-06-27 | Paradigm Capital | Buy | Maintains | |
| 2012-06-22 | Jefferies | Buy | Maintains | |
| 2025-01-30 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2024-08-02 | TD COWEN | Outperform | Hold | Downgrade |
| 2024-07-31 | TRUIST SECURITIES | Hold | Hold | Maintains |
| 2024-02-05 | CRISPIDEA PRIVATE LIMITED | Buy | Buy | Maintains |
| 2023-12-20 | TRUIST SECURITIES | Hold | Hold | Maintains |
| 2023-09-28 | CRISPIDEA PRIVATE LIMITED | Buy | Buy | Maintains |
| 2025-02-06 | Jefferies | Buy | Hold | Downgrade |
| 2025-02-23 | TD COWEN | Hold | Hold | Maintains |
| 2025-02-19 | TRUIST SECURITIES | Hold | Hold | Maintains |
| 2024-10-30 | TD COWEN | Hold | Hold | Maintains |
| 2024-10-30 | TRUIST SECURITIES | Hold | Hold | Maintains |
| 2025-05-02 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2025-07-09 | TD COWEN | Hold | Hold | Maintains |
| 2025-04-29 | TRUIST SECURITIES | Hold | Hold | Maintains |
